213 related articles for article (PubMed ID: 28150519)
41. The MOVEMENT Trial.
Holm M; Tornvall P; Henareh L; Jensen U; Golster N; Alström P; Santos-Pardo I; Witt N; Fedchenko N; Venetsanos D; Beck O; van der Linden J
J Am Heart Assoc; 2019 Jan; 8(2):e010152. PubMed ID: 30636504
[TBL] [Abstract][Full Text] [Related]
42. Effects of Methylnaltrexone on Ticagrelor-Induced Antiplatelet Effects in Coronary Artery Disease Patients Treated With Morphine.
Franchi F; Rollini F; Park Y; Hu J; Kureti M; Rivas Rios J; Faz G; Yaranov D; Been L; Pineda AM; Suryadevara S; Soffer D; Zenni MM; Bass TA; Angiolillo DJ
JACC Cardiovasc Interv; 2019 Aug; 12(16):1538-1549. PubMed ID: 31377269
[TBL] [Abstract][Full Text] [Related]
43. Pharmacokinetics, pharmacodynamics, and safety of ticagrelor in volunteers with severe renal impairment.
Butler K; Teng R
J Clin Pharmacol; 2012 Sep; 52(9):1388-98. PubMed ID: 21960668
[TBL] [Abstract][Full Text] [Related]
44. Crushed sublingual versus oral ticagrelor administration strategies in patients with unstable angina. A pharmacokinetic/pharmacodynamic study.
Niezgoda P; Sikora J; Barańska M; Sikora A; Buszko K; Siemińska E; Marszałł MP; Siller-Matula JM; Jilma B; Alexopoulos D; Fabiszak T; Kubica J
Thromb Haemost; 2017 Apr; 117(4):718-726. PubMed ID: 28203684
[TBL] [Abstract][Full Text] [Related]
45. How Long Does It Take for Clopidogrel and Ticagrelor to Inhibit Platelets in Patients Undergoing Primary Percutaneous Coronary Intervention? A Detailed Pharmacodynamic Analysis: Time Course of Platelet Reactivity in STEMI (TOPS).
Bergmeijer TO; Godschalk TC; Janssen PWA; Berge KVD; Breet NJ; Kelder JC; Hackeng CM; Ten Berg JM
Semin Thromb Hemost; 2017 Jun; 43(4):439-446. PubMed ID: 28561235
[TBL] [Abstract][Full Text] [Related]
46. Antiplatelet Effect of Different Loading Doses of Ticagrelor in Patients With Non-ST-Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: The APELOT Trial.
Liu HL; Wei YJ; Ding P; Zhang J; Li TC; Wang B; Wang MS; Li YT; Zhang JJ; Ren YH; Tang Q; Luo JP; Yang SL; Ma HY; Liu Y; Han W; Li Y; Jin ZG; Jin LM
Can J Cardiol; 2017 Dec; 33(12):1675-1682. PubMed ID: 29173606
[TBL] [Abstract][Full Text] [Related]
47. Pharmacokinetics and tolerability of single and multiple doses of ticagrelor in healthy Chinese subjects: an open-label, sequential, two-cohort, single-centre study.
Li H; Butler K; Yang L; Yang Z; Teng R
Clin Drug Investig; 2012 Feb; 32(2):87-97. PubMed ID: 22168538
[TBL] [Abstract][Full Text] [Related]
48. Comparison of pharmacodynamics between low dose ticagrelor and clopidogrel after loading and maintenance doses in healthy Korean subjects.
Guo LZ; Kim MH; Jin CD; Lee JY; Yi SJ; Park MK; Cho YR; Park TH
Platelets; 2015; 26(6):563-9. PubMed ID: 25275429
[TBL] [Abstract][Full Text] [Related]
49. Impact of non-inhibited platelet supplementation on platelet reactivity in patients treated with prasugrel or ticagrelor for an acute coronary syndrome: An ex vivo study.
Bonhomme F; Bonvini R; Reny JL; Poncet A; Fontana P
Platelets; 2015; 26(4):324-30. PubMed ID: 25905916
[TBL] [Abstract][Full Text] [Related]
50. Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in patients with stable coronary artery disease: Results of the SWAP-2 Study (Switching Anti Platelet-2).
Angiolillo DJ; Curzen N; Gurbel P; Vaitkus P; Lipkin F; Li W; Jakubowski JA; Zettler M; Effron MB; Trenk D
J Am Coll Cardiol; 2014 Apr; 63(15):1500-9. PubMed ID: 24333493
[TBL] [Abstract][Full Text] [Related]
51. Pharmacodynamic Effects of Ticagrelor Dosing Regimens in Patients on Maintenance Ticagrelor Therapy: Results From a Prospective, Randomized, Double-Blind Investigation.
Cho JR; Rollini F; Franchi F; DeGroat C; Bhatti M; Dunn EC; Ferrante E; Muniz-Lozano A; Suryadevara S; Zenni MM; Guzman LA; Bass TA; Angiolillo DJ
JACC Cardiovasc Interv; 2015 Jul; 8(8):1075-1083. PubMed ID: 26117466
[TBL] [Abstract][Full Text] [Related]
52. Newly Formed Reticulated Platelets Undermine Pharmacokinetically Short-Lived Antiplatelet Therapies.
Armstrong PC; Hoefer T; Knowles RB; Tucker AT; Hayman MA; Ferreira PM; Chan MV; Warner TD
Arterioscler Thromb Vasc Biol; 2017 May; 37(5):949-956. PubMed ID: 28279968
[TBL] [Abstract][Full Text] [Related]
53. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
[TBL] [Abstract][Full Text] [Related]
54. METoclopramide Administration as a Strategy to Overcome MORPHine-ticagrelOr Interaction in PatientS with Unstable Angina PectorIS-The METAMORPHOSIS Trial.
Sikora J; Niezgoda P; Barańska M; Buszko K; Skibińska N; Sroka W; Pstrągowski K; Siller-Matula J; Bernd J; Gorog D; Navarese EP; Marszałł MP; Kubica J
Thromb Haemost; 2018 Dec; 118(12):2126-2133. PubMed ID: 30453344
[TBL] [Abstract][Full Text] [Related]
55. Effect of Pre-Hospital Ticagrelor During the First 24 h After Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction: The ATLANTIC-H²⁴ Analysis.
Montalescot G; van 't Hof AW; Bolognese L; Cantor WJ; Cequier A; Chettibi M; Collet JP; Goodman SG; Hammett CJ; Huber K; Janzon M; Lapostolle F; Lassen JF; Licour M; Merkely B; Salhi N; Silvain J; Storey RF; Ten Berg JM; Tsatsaris A; Zeymer U; Vicaut E; Hamm CW;
JACC Cardiovasc Interv; 2016 Apr; 9(7):646-56. PubMed ID: 26952907
[TBL] [Abstract][Full Text] [Related]
56. Platelet function recovery after ticagrelor withdrawal in patients awaiting urgent coronary surgery.
Hansson EC; Malm CJ; Hesse C; Hornestam B; Dellborg M; Rexius H; Jeppsson A
Eur J Cardiothorac Surg; 2017 Apr; 51(4):633-637. PubMed ID: 28007881
[TBL] [Abstract][Full Text] [Related]
57. Impact of immature platelets on platelet response to ticagrelor and prasugrel in patients with acute coronary syndrome.
Bernlochner I; Goedel A; Plischke C; Schüpke S; Haller B; Schulz C; Mayer K; Morath T; Braun S; Schunkert H; Siess W; Kastrati A; Laugwitz KL
Eur Heart J; 2015 Dec; 36(45):3202-10. PubMed ID: 26216931
[TBL] [Abstract][Full Text] [Related]
58. Pharmacodynamics, pharmacokinetics and safety of ticagrelor in Asian patients with stable coronary artery disease.
Hiasa Y; Teng R; Emanuelsson H
Cardiovasc Interv Ther; 2014 Oct; 29(4):324-33. PubMed ID: 24935072
[TBL] [Abstract][Full Text] [Related]
59. Platelet reactivity in patients with impaired renal function receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
Barbieri L; Pergolini P; Verdoia M; Rolla R; Nardin M; Marino P; Bellomo G; Suryapranata H; De Luca G;
Vascul Pharmacol; 2016 Apr; 79():11-15. PubMed ID: 26518440
[TBL] [Abstract][Full Text] [Related]
60. Pharmacodynamic effects during the transition between cangrelor and ticagrelor.
Schneider DJ; Agarwal Z; Seecheran N; Keating FK; Gogo P
JACC Cardiovasc Interv; 2014 Apr; 7(4):435-42. PubMed ID: 24656538
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
